MIT Universities Allied for Essential Medicines

PIH/David Walton

You bring kindness, and your kindness is good. But it will not cure this AIDS. I know there is medicine in your country for people like you. But why not here, for people like me?

Pharmaceutical industry expenditures Worldwide, % R&D 25% Profits 30% Operational and material costs 32% Marketing and administration

Flickr/MikeBlythFlickr/MikeBlyth Drs. Prusoff and Lin at Yale discovered that d4t (stavudine, Zerit) is active against HIV. D4t became a key first-line antiretroviral. Because Yale licensed d4t exclusively to Bristol Myers Squibb, the company set a monopoly price (too high for poor patients)

Impact of Generic Competition: Uganda

Magnum Photos/Francesco Zizola In South Africa, MSF and the Treatment Action Campaign bought low-price, generic d4t to save the lives of the HIV+ poor. The generic d4t was technically illegal, because it infringed on Bristol Myers Squibb’s patent on d4t in South Africa.

Before ARV therapyAfter six months on ARV therapy PIH/David Walton Antiretroviral treatment can literally bring a dying patient back to life. Here, Joseph in Haiti, treated by Partners in Health.

Bristol Myers Squibb launched a lawsuit for patent infringement against the South African generic company, essentially asserting that it is acceptable to die of a treatable infection so long as you are poor enough.

“The Scientist’s Story” “I once helped create a drug that could enable millions of people to lead better and longer lives…More recently, it became apparent that the drug Dr. Lin and I had developed was not reaching millions of desperately suffering people because they lacked the money to purchase it.” NYTimes Editorial: March 19, 2001 By William Prusoff.

Role of Academic Research  Academic patents in 1 in every 5 of the most innovative Rx (FDA priority review)  Academic patents in 1 in every 4 HIV Rx.  In 44% of cases, universities filed for patent protection in developing world. Sampat, Am J. Pub. H., 2009

PhRMA Sales by Geographic Area

Gener-X Patent Global Access Licensing

The New “Scientist’s Story” Dr. Kishor M. Wasan

Meeting with Harvard’s President Just prior to SPS (October 2009)

The Statement of Principles and Strategies for Equitable Dissemination of Medical Technologies (SPS) is Born Yale Provost agrees to articulate policies Discuss Stakeholder Meeting, Committee on Global Access Licensing with Dean of Public Health Crimson op-ed exchange Faculty outreach for Working Group on Licensing First meeting with OTD, friendly Petition to Provost Yale monthly OTD meetings Provost and TTO Head reveal plans to develop multi- university agreement Meeting with OTD and CEOs, unfriendly Multi- University Roundtable Say Yes To Drugs Campaign SPS Launched Meeting with Harvard President

Current Signatories InstitutionSigning Date Association of University Technology Managers11/9/2009 Boston Univ11/9/2009 Brown Univ11/9/2009 Harvard Univ11/9/2009 Univ of Pennsylvania11/9/2009 Yale Univ11/9/2009 Oregon Health & Science University11/9/2009 National Institutes of Health11/10/2009 University of Illinois Chicago11/10/2009 University of Illinois Urbana-Champaign11/11/2009 Centers for Disease Control and Prevention11/12/2009 University of Vermont and State Agricultural College11/19/2009 Duke University and Duke Medicine12/1/2009 University of British Columbia1/10/2010 Bilkent University1/27/2010 El Colegio de México1/27/2010 New York University2/4/2010 Tecnologico de Monterrey2/13/2010 Jawaharlal Nehru University2/18/2010 Najit Technologies, Inc.3/4/2010 Brigham & Women's Hospital3/15/2010 Florida State University3/29/2010 Massachusetts General Hospital3/29/2010

Mission Statement The mission of MIT is to advance knowledge and educate students in science, technology, and other areas of scholarship that will best serve the nation and the world in the 21st century. The Institute is committed to generating, disseminating, and preserving knowledge, and to working with others to bring this knowledge to bear on the world's great challenges. MIT is dedicated to providing its students with an education that combines rigorous academic study and the excitement of discovery with the support and intellectual stimulation of a diverse campus community. We seek to develop in each member of the MIT community the ability and passion to work wisely, creatively, and effectively for the betterment of humankind.

Our Vision Universities and publicly funded research institutions will be part of the solution to the access to medicines crisis by promoting medical innovation in the public interest and ensuring that all people regardless of income have access to essential medicines and other health-related technologies. Our Mission As a private non-profit organization rooted in a movement of university students, UAEM aims to - promote access to medicines for people in developing countries by changing norms and practices around university patenting and licensing - ensure that university medical research meets the needs of the majority of the world’s population - empower students to respond to the access and innovation crisis